Literature DB >> 32816910

Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST.

Katherine E Chaney1, Melissa R Perrino1, Leah J Kershner1, Ami V Patel1, Jianqiang Wu1, Kwangmin Choi1, Tilat A Rizvi1, Eva Dombi2, Sara Szabo3, David A Largaespada4, Nancy Ratner5.   

Abstract

Plexiform neurofibromas are benign nerve sheath Schwann cell tumors characterized by biallelic mutations in the neurofibromatosis type 1 (NF1) tumor suppressor gene. Atypical neurofibromas show additional frequent loss of CDKN2A/Ink4a/Arf and may be precursor lesions of aggressive malignant peripheral nerve sheath tumors (MPNST). Here we combined loss of Nf1 in developing Schwann cells with global Ink4a/Arf loss and identified paraspinal plexiform neurofibromas and atypical neurofibromas. Upon transplantation, atypical neurofibromas generated genetically engineered mice (GEM)-PNST similar to human MPNST, and tumors showed reduced p16INK4a protein and reduced senescence markers, confirming susceptibility to transformation. Superficial GEM-PNST contained regions of nerve-associated plexiform neurofibromas or atypical neurofibromas and grew rapidly on transplantation. Transcriptome analyses showed similarities to corresponding human tumors. Thus, we recapitulated nerve tumor progression in NF1 and provided preclinical platforms for testing therapies at each tumor grade. These results support a tumor progression model in which loss of NF1 in Schwann cells drives plexiform neurofibromas formation, additional loss of Ink4a/Arf contributes to atypical neurofibromas formation, and further changes underlie transformation to MPNST. SIGNIFICANCE: New mouse models recapitulate the stepwise progression of NF1 tumors and will be useful to define effective treatments that halt tumor growth and tumor progression in NF1. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32816910      PMCID: PMC7968129          DOI: 10.1158/0008-5472.CAN-19-1429

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  50 in total

Review 1.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

2.  Mitotic recombination effects homozygosity for NF1 germline mutations in neurofibromas.

Authors:  E Serra; T Rosenbaum; M Nadal; U Winner; E Ars; X Estivill; C Lázaro
Journal:  Nat Genet       Date:  2001-07       Impact factor: 38.330

3.  The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.

Authors:  A Pemov; H Li; R Patidar; N F Hansen; S Sindiri; S W Hartley; J S Wei; A Elkahloun; S C Chandrasekharappa; J F Boland; S Bass; J C Mullikin; J Khan; B C Widemann; M R Wallace; D R Stewart
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

4.  PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.

Authors:  Thomas De Raedt; Eline Beert; Eric Pasmant; Armelle Luscan; Hilde Brems; Nicolas Ortonne; Kristian Helin; Jason L Hornick; Victor Mautner; Hildegard Kehrer-Sawatzki; Wade Clapp; James Bradner; Michel Vidaud; Meena Upadhyaya; Eric Legius; Karen Cichowski
Journal:  Nature       Date:  2014-08-13       Impact factor: 49.962

5.  A negative feedback signaling network underlies oncogene-induced senescence.

Authors:  Stéphanie Courtois-Cox; Sybil M Genther Williams; Elizabeth E Reczek; Bryan W Johnson; Lauren T McGillicuddy; Cory M Johannessen; Pablo E Hollstein; Mia MacCollin; Karen Cichowski
Journal:  Cancer Cell       Date:  2006-12       Impact factor: 31.743

Review 6.  p53-Dependent and -independent functions of the Arf tumor suppressor.

Authors:  C J Sherr; D Bertwistle; W DEN Besten; M-L Kuo; M Sugimoto; K Tago; R T Williams; F Zindy; M F Roussel
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2005

7.  Identification of the gene immediately downstream of the murine INK4a/ARF locus.

Authors:  C Pantoja; I Palmero; M Serrano
Journal:  Exp Gerontol       Date:  2001-08       Impact factor: 4.032

8.  Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo.

Authors:  Florence Debacq-Chainiaux; Jorge D Erusalimsky; Judith Campisi; Olivier Toussaint
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

Review 9.  Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways.

Authors:  Daniela Katz; Alexander Lazar; Dina Lev
Journal:  Expert Rev Mol Med       Date:  2009-10-19       Impact factor: 5.600

10.  Comparative pathology of nerve sheath tumors in mouse models and humans.

Authors:  Anat O Stemmer-Rachamimov; David N Louis; Gunnlaugur P Nielsen; Cristina R Antonescu; Alexander D Borowsky; Roderick T Bronson; Dennis K Burns; Pascale Cervera; Margaret E McLaughlin; Guido Reifenberger; Michael C Schmale; Mia MacCollin; Richard C Chao; Karen Cichowski; Michel Kalamarides; Shanta M Messerli; Andrea I McClatchey; Michiko Niwa-Kawakita; Nancy Ratner; Karlyne M Reilly; Yuan Zhu; Marco Giovannini
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

View more
  9 in total

1.  Chromosomal translocations inactivating CDKN2A support a single path for malignant peripheral nerve sheath tumor initiation.

Authors:  Cleofe Romagosa; Eduard Serra; Bernat Gel; Miriam Magallón-Lorenz; Juana Fernández-Rodríguez; Ernest Terribas; Edgar Creus-Batchiller; Anna Estival; Diana Perez Sidelnikova; Héctor Salvador; Alberto Villanueva; Ignacio Blanco; Meritxell Carrió; Conxi Lázaro
Journal:  Hum Genet       Date:  2021-05-31       Impact factor: 4.132

Review 2.  Spontaneous and Engineered Large Animal Models of Neurofibromatosis Type 1.

Authors:  Sara H Osum; Adrienne L Watson; David A Largaespada
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 6.208

3.  A genetic mouse model with postnatal Nf1 and p53 loss recapitulates the histology and transcriptome of human malignant peripheral nerve sheath tumor.

Authors:  Akira Inoue; Laura J Janke; Brian L Gudenas; Hongjian Jin; Yiping Fan; Joshua Paré; Michael R Clay; Paul A Northcott; Angela C Hirbe; Xinwei Cao
Journal:  Neurooncol Adv       Date:  2021-09-10

Review 4.  Targeted Therapies for the Neurofibromatoses.

Authors:  Lauren D Sanchez; Ashley Bui; Laura J Klesse
Journal:  Cancers (Basel)       Date:  2021-11-30       Impact factor: 6.639

Review 5.  Malignant peripheral nerve sheath tumor: models, biology, and translation.

Authors:  Bandarigoda N Somatilaka; Ali Sadek; Renee M McKay; Lu Q Le
Journal:  Oncogene       Date:  2022-04-07       Impact factor: 8.756

Review 6.  The Role of CDK Pathway Dysregulation and Its Therapeutic Potential in Soft Tissue Sarcoma.

Authors:  Johannes Tobias Thiel; Adrien Daigeler; Jonas Kolbenschlag; Katarzyna Rachunek; Sebastian Hoffmann
Journal:  Cancers (Basel)       Date:  2022-07-12       Impact factor: 6.575

7.  Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors in a Neurofibromin-Dependent Manner.

Authors:  Garrett Alewine; Jerrica Knight; Adithya Ghantae; Christina Mamrega; Bashnona Attiah; Robert A Coover; Cale D Fahrenholtz
Journal:  J Pers Med       Date:  2022-06-30

8.  Screening of potential novel candidate genes in schwannomatosis patients.

Authors:  Cristina Perez-Becerril; Andrew J Wallace; Helene Schlecht; Naomi L Bowers; Philip T Smith; Carolyn Gokhale; Helen Eaton; Chris Charlton; Rachel Robinson; Ruth S Charlton; D Gareth Evans; Miriam J Smith
Journal:  Hum Mutat       Date:  2022-06-27       Impact factor: 4.700

Review 9.  Review of Pediatric Head and Neck Neoplasms that Raise the Possibility of a Cancer Predisposition Syndrome.

Authors:  Nahir Cortes-Santiago; Kalyani Patel
Journal:  Head Neck Pathol       Date:  2021-03-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.